Aditxt, INC 8-K filings

Aditxt Inc. filed an amendment to its 8-K report to remove certain merger agreement details and to disclose an exchange of Evofem preferred stock for a new series of Aditxt preferred stock, along with related registration rights.

Aditxt, Inc. has defaulted on a $55,256 loan from Sixth Borough Capital Fund, LP, raising concerns about the company's financial stability.

Aditxt, Inc. has secured $775,000 in cash proceeds through the issuance of senior notes and commitment shares to accredited investors.

Aditxt, Inc. has issued a senior note for $93,918.75 to an accredited investor, with a purchase price of $75,135.00, reflecting an original issue discount.

Aditxt, Inc. has entered into an unsecured promissory note for an additional $20,000 at 15% interest while also facing a lease default notice for over $590,000.

Aditxt, Inc. has successfully priced a $4.2 million private placement, issuing convertible preferred stock, super voting preferred stock and warrants.

Aditxt, Inc. has entered into a common stock purchase agreement with Seven Knots, LLC, providing access to up to $150 million in funding.

Aditxt and Evofem have reinstated their merger agreement, previously terminated due to a missed payment, with a new amendment that includes a $1 million payment and revised investment terms.

Aditxt's merger agreement with Evofem Biosciences has been terminated by Evofem due to Aditxt's failure to provide the initial equity investment.

Aditxt, Inc. has obtained a $230,000 unsecured loan from Sixth Borough Capital Fund, LP, with a maturity date of April 19, 2024, or upon an event of default.

Aditxt has signed a definitive agreement to acquire Appili Therapeutics, a biopharmaceutical company with a focus on infectious diseases and medical countermeasures, for approximately $20 million.

Aditxt, Inc. obtained a $300,000 unsecured loan with an 8.5% interest rate while also facing a lease default for $40,707 in unpaid rent.

Aditxt, Inc. and Evofem Biosciences, Inc. have amended their merger agreement, modifying financial obligations and extending the timeline for filing the joint proxy statement.

Aditxt, Inc. received $232,000 in loans from its CEO and Chief Innovation Officer, evidenced by an unsecured promissory note with an 8.5% interest rate.

Aditxt has reassigned its debt obligations back to Baker Brothers, resolving a recent default and adjusting the outstanding balance of its secured notes.

Aditxt, Inc. has filed an amendment to its previous 8-K report, removing financial statements and pro forma information related to its merger with Evofem Biosciences.

Aditxt, Inc. has engaged Dawson James Securities as a financial advisor to explore potential business combinations, agreeing to pay an initial fee and a transaction fee upon successful completion of a deal.

Aditxt, Inc. has received a $205,000 unsecured loan from its CEO, Amro Albanna, with an 8.5% interest rate, due by August 15, 2024, or upon an event of default.

Aditxt Inc. has defaulted on its secured notes and business loans after failing to make a required payment, potentially impacting its financial stability.

Aditxt, Inc. has entered into an unsecured promissory note with its CEO, Amro Albanna, for a $30,000 loan at an 8.5% interest rate, due by August 7, 2024.

Aditxt, Inc. has amended its secured promissory notes, extending the maturity date of the January 2024 notes to February 29, 2024, and increasing the principal balance of the September 2024 notes.

Aditxt and Evofem have amended their merger agreement for a second time, pushing back the loan date, termination date, and joint proxy statement filing date.

Aditxt, Inc. has acquired a portfolio of EEG brain monitoring technologies and devices from Brain Scientific, Inc., including the NeuroCap and NeuroEEG, to expand its presence in the neurology market.

Aditxt, Inc. has entered into a $3.6 million loan agreement to refinance existing debt and provide additional working capital.

Aditxt Inc. issued 296,296 shares of common stock to an investor to settle a lawsuit, as part of a previously announced agreement.